Virbac FY 2025 presentation: 7.9% organic growth amid FX headwinds

Virbac reported FY2025 revenue of €1,464.7m (up 8.7% reported; 7.9% at constant rates) with adjusted EBIT €234.4m (16.0% margin) and net income €150.5m (+3.2% y/y); Q4 revenue missed slightly at ~$362m vs $366.1m consensus. Management highlighted record R&D spend (€115.1m), nine licensing deals, and the Dec‑2025 Thyronorm bolt‑on (~€27m in‑market revenue) and guided 2026 revenue growth of 5.5–7.5% (constant scope) and an adjusted EBIT margin around 17%. Free cash flow was €92.6m before dividends (€81.4m after), net debt €172.8m (net debt/EBITDA 0.51), and the stock rose 4.42% to €333.5 despite FX headwinds, supporting a constructive near‑term outlook.

Analysis

Virbac’s playbook — heavier innovation spend, targeted bolt‑on deals and expanding manufacturing capacity — amplifies a small‑cap re‑rating thesis but also changes the competitive map. Smaller, fast‑moving specialists with integrated nutrition or specialty endocrinology franchises can take share in premium companion segments, while large incumbents with broader scale may respond by accelerating global commercialization of existing assets rather than outspending on early‑stage discovery.

A key second‑order supply‑chain effect is the gradual onshoring of critical biologics capacity: as the company builds internal manufacturing, contract manufacturers supplying competitors will see demand reallocated, tightening capacity premiums for third‑party CMOs. Currency volatility in emerging markets creates asymmetric P&L risk — operational outperformance can be eroded quickly by translation effects if hedging is passive — so near‑term EPS beats are more fragile than headline growth suggests.

Near‑term catalysts to watch are execution milestones (manufacturing ramp, integration progress and regulatory clearances) over the next 6–12 months; these will determine whether the market re‑rates the business sustainably or treats recent strength as transient. Tail risks include a setback in a priority biologic or a sharp adverse FX swing in Latin America; both could compress free cash flow and force a pause in buy‑and‑build activity, reversing sentiment within quarters.

Key Decisions for Investors

• Long VIRP (EPA:VIRP) equity, 6–12 month horizon. Size 2–4% of risk capital. Rationale: asymmetric upside from re‑rating if manufacture/milestone cadence executes; set stop loss at -15% and trim half at +30% to lock gains.
• Buy VIRP 9–12 month call spread to limit downside while capturing rerating (buy nearer‑term ATM call, sell 20–25% OTM call). Max loss = premium paid; target 2.5–4x payoff if catalysts land.
• Pair trade: long VIRP / short ZTS (NYSE:ZTS) equal notional, 9–12 month horizon. Expect outperformance if small‑cap innovation premium sustains; risk if sectorwide demand shock boosts large‑cap scalability. Keep pair size to 1–2% net exposure.
• Hedge currency exposure: if allocating to Virbac, buy EUR put vs USD or short emerging‑market FX exposure for 3–6 months to protect against translation swings. Hedge cost justified if position >2% of portfolio as FX can wipe out operational beats quickly.